1. Home
  2. GXAI vs KZIA Comparison

GXAI vs KZIA Comparison

Compare GXAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GXAI
  • KZIA
  • Stock Information
  • Founded
  • GXAI 2021
  • KZIA 1994
  • Country
  • GXAI United States
  • KZIA Australia
  • Employees
  • GXAI N/A
  • KZIA N/A
  • Industry
  • GXAI
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GXAI
  • KZIA Health Care
  • Exchange
  • GXAI Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • GXAI 7.5M
  • KZIA 7.8M
  • IPO Year
  • GXAI 2023
  • KZIA 1999
  • Fundamental
  • Price
  • GXAI $1.53
  • KZIA $1.29
  • Analyst Decision
  • GXAI
  • KZIA Strong Buy
  • Analyst Count
  • GXAI 0
  • KZIA 2
  • Target Price
  • GXAI N/A
  • KZIA $11.50
  • AVG Volume (30 Days)
  • GXAI 707.0K
  • KZIA 5.5M
  • Earning Date
  • GXAI 03-26-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • GXAI N/A
  • KZIA N/A
  • EPS Growth
  • GXAI N/A
  • KZIA N/A
  • EPS
  • GXAI N/A
  • KZIA N/A
  • Revenue
  • GXAI $2,979.00
  • KZIA $1,655,324.00
  • Revenue This Year
  • GXAI N/A
  • KZIA $806.89
  • Revenue Next Year
  • GXAI N/A
  • KZIA N/A
  • P/E Ratio
  • GXAI N/A
  • KZIA N/A
  • Revenue Growth
  • GXAI N/A
  • KZIA 248000.00
  • 52 Week Low
  • GXAI $1.01
  • KZIA $1.25
  • 52 Week High
  • GXAI $19.20
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • GXAI 40.09
  • KZIA 39.50
  • Support Level
  • GXAI $1.35
  • KZIA $1.31
  • Resistance Level
  • GXAI $2.22
  • KZIA $2.64
  • Average True Range (ATR)
  • GXAI 0.15
  • KZIA 0.24
  • MACD
  • GXAI -0.03
  • KZIA 0.09
  • Stochastic Oscillator
  • GXAI 19.54
  • KZIA 14.29

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: